Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Cholesterol cream for skin barrier and symptoms in young people with atopic dermatitis

Tests a cholesterol cream against a placebo cream in children with atopic dermatitis.

Plain-language title generated from the registry record
Registry title: A Study on the Efficacy of 2% Cholesterol Cream in Atopic Dermatitis

Key facts

Where
Bangkok, ThailandSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 7 and 17 years old?

Source: NCT07503197, who can take part

Where in Thailand

  • Institute of dermatology(inderm)Bangkok, ThailandNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Institute of Dermatology, Thailand
Trial code
NCT07503197
Record updated
14 May 2026
Original description
Atopic dermatitis is a common chronic inflammatory skin condition characterized by impaired skin barrier function, leading to increased transepidermal water loss (TEWL), dry skin, and itching. Restoration of the skin barrier is an important component of treatment. Cholesterol is a key lipid in the stratum corneum that plays a role in maintaining skin barrier integrity.Read full original descriptionShow less

A Pilot Study on the Efficacy of 2% Cholesterol Cream in Preventing Transepidermal Water Loss and Clinical Symptoms in Mild to Moderate Atopic Dermatitis.

Atopic dermatitis is a common chronic inflammatory skin condition characterized by impaired skin barrier function, leading to increased transepidermal water loss (TEWL), dry skin, and itching. Restoration of the skin barrier is an important component of treatment. Cholesterol is a key lipid in the stratum corneum that plays a role in maintaining skin barrier integrity.

This study aims to evaluate the efficacy and safety of 2% cholesterol cream in improving skin barrier function and clinical symptoms in patients with mild to moderate atopic dermatitis aged 7-17 years. Participants will be randomly assigned to receive either 2% cholesterol cream or a placebo (cream base), applied twice daily for 12 weeks.

Outcomes will include measurements of transepidermal water loss (TEWL), skin hydration, skin pH, Investigator's Global Assessment (IGA), Eczema Area and Severity Index (EASI), and pruritus numeric rating scale (NRS). The results of this study may support the use of cholesterol-containing topical formulations as a safe and effective treatment option for atopic dermatitis.

Inclusion: Thai nationality; Aged between 7-17 years; Able to read and write Thai fluently; Clinically diagnosed with mild to moderate atopic dermatitis, with lesions located on both antecubital fossae, according to the Hanifin and Rajka criteria; Investigator's Global Assessment (IGA) score of 1-3; Eczema Area and Severity Index (EASI) score between 0.2-21.

Exclusion: Use of systemic immunosuppressive therapy (e.g., prednisolone, dupilumab, JAK inhibitors); Presence of other dermatologic conditions other than atopic dermatitis; History of chronic infections such as hepatitis B, hepatitis C, herpes zoster, or tuberculosis; History of any malignancy; Pregnant or breastfeeding women, or those planning pregnancy during the study period.

ClinicalTrials.gov NCT07503197